ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 fusion	Melanoma	ROS1 fusion	Melanoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ROS1 fusion	Melanoma	ROS1 fusion	Melanoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	AB-106 Sensitive: B - Late Trials AB-106 Sensitive : B	AB-106 Sensitive: B - Late Trials AB-106 Sensitive : B
ROS1 fusion	Solid Tumor	ROS1 fusion	Solid Tumor	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	durvalumab Resistant: C2 – Inclusion Criteria durvalumab Resistant : C2	durvalumab Resistant: C2 – Inclusion Criteria durvalumab Resistant : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ROS1 fusion	Lung Non-Squamous Non-Small Cell Cancer	ROS1 fusion	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab Sensitive : C2	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab Sensitive : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	SAF-189 Sensitive: C3 – Early Trials SAF-189 Sensitive : C3	SAF-189 Sensitive: C3 – Early Trials SAF-189 Sensitive : C3
ROS1 fusion	Lung Non-Squamous Non-Small Cell Cancer	ROS1 fusion	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C4 – Case Studies bevacizumab + crizotinib Sensitive : C4	bevacizumab + crizotinib Sensitive: C4 – Case Studies bevacizumab + crizotinib Sensitive : C4
ROS1 fusion	Glioblastoma	ROS1 fusion	Glioblastoma	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D
ROS1 fusion	Solid Tumor	ROS1 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D

ROS1 fusion

Associations